Featured Publications

  • Nature 2012 April (483) 100-103

  • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

  • Anirudh Prahallad, Chong Sun, Sidong Huang, Federica Di Nicolantonio, Ramon Salazar, Davide Zecchin, Roderick L. Beijersbergen, Alberto Bardelli and Rene Bernards

  • View Article

  • Proc Natl Acad Sci U S A.  2011 December (Epub ahead of print)

  • Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

  • Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A

  • View Article

  • Proc Natl Acad Sci U S A 2011 September (109)

  • Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells

  • Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH.

  • View Article

  • JAMA 2010 October (304) 1812-1820

  • Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

  • Roock WD, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Cutsem EV, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S

  • View Article

  • J Clin Invest.  2010 August (120) 2858-66

  • Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.

  • Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A.

  • View Article

  • Clin Cancer Res.  2010 July (16) 3670-83

  • Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

  • O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR.

  • View Article

  • Nature 2010 May (464) 431-5

  • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

  • Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

  • View Article

  • Molecular Therapy 2010 May (18) 983-986

  • Frequent Endonuclease Cleavage at Off-target Locations In Vivo

  • Lisa M Petek, David W Russell and Daniel G Miller

  • View Article

  • AACR 2010 April (Poster Session)

  • Endogenous expression of oncogenic PI3K mutation leads to accumulation of anti-apoptotic proteins at mitochondria

  • Mitologics Ltd.

  • View Article

  • AACR 2010 April (Poster Session)

  • The use of X-MAN isogenic cell lines to define PI3-kinase inhibitor activity profiles

  • Hypoxium Ltd.

  • View Article

  • J Clin Oncol. 2010 March (28) 1181-9

  • Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

  • Bardelli A, Siena S.

  • View Article

  • Cell  2010 January (140) 209-21

  • Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

  • Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R.

  • View Article

  • Science.  2009 September (325) 1555-9

  • Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.

  • Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N.

  • View Article

  • EMBO Mol Med.  2009 September (1) 315-22

  • Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

  • Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A.

  • View Article

  • Proc Natl Acad Sci U S A. 2009 February (106) 2835-40

  • Knockin of mutant PIK3CA activates multiple oncogenic pathways.

  • Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH.

  • View Article

  • Proc Natl Acad Sci U S A.  2008 December (105) 20864-9

  • Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.

  • Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A.

  • View Article

  • J Clin Oncol.  2008 December (26) 5705-12

  • Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  • Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

  • View Article

  • J. Clin. Invest. 2008 April (118) 1571-7

  • Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer.

  • Rogers CS, Hao Y, Rokhlina T, Samuel M, Stoltz DA, Li Y, Petroff E, Vermeer DW, Kabel AC, Yan Z, Spate L, Wax D, Murphy CN, Rieke A, Whitworth K, Linville ML, Korte SW, Engelhardt JF, Welsh MJ, Prather RS.

  • View Article

  • J. Clin. Invest. 2008 April ( 118) 1578–1583

  • Adeno-associated virus–targeted disruption of the CFTR gene in cloned ferrets

  • Sun X, Yan Z, Yi Y, Li Z, Lei D, Rogers CS, Chen J, Zhang Y, Welsh MJ, Leno GH, Engelhardt JF.

  • View Article

  • Biol Proced Online. 2007 December (9) 84-90

  • Development of human gene reporter cell lines using rAAV mediated homologous recombination

  • Fernandez SL, Russell DW, Hurlin PJ.

  • View Article

  • Cancer Res.  2007 March (67) 2643-8

  • Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  • Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A.

  • View Article

  • Mol Ther.  2007 January (15) 1740

  • AAV Vectors, Insertional Mutagenesis, and Cancer

  • David W Russell

  • View Article

  • Curr Protoc Mol Biol. 2003 January () 9.15.1-9.15.2

  • INACTIVATION OF GENES IN MAMMALIAN CELLS Human Somatic Cell Gene Targeting

  • Todd Waldman, Carolyn Lee, Tagvor G. Nishanian, and Jung-Sik Kim

  • View Article